Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-weekly Subcutaneous Doses of PB-119 to Patients With Type 2 Diabetes Mellitus (T2DM) Not Well-controlled by Metformin Monotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2020
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors PegBio
- 21 Jan 2020 Status changed from recruiting to completed.
- 31 Jul 2018 New trial record